Oxford BioDynamics collaborates with National Cancer Institute in prostate cancer clinical trial

Oxford BioDynamics Plc (AIM: OBD), a pioneering biotechnology company, has announced its participation in a significant clinical trial led by the National Cancer Institute (NCI) ... Read More